Tried Multiple Migraine Treatments Without Relief? Atogepant May Help
Release Date: 10/31/2025
Study Says Cannabis Shows Promise for Migraine Relief
Migraine Minute News Update
First-of-its-kind study: A new study suggests that a combination of THC + CBD works better than placebo, THC alone, or CBD alone for reducing migraine pain and symptoms. Molly O’Brien breaks it down in this Migraine Minute News Update. Read More: Script: For the first time, researchers tested cannabis in a placebo-controlled trial for migraine… and results suggest it could be effective. A recent study found that when treating migraine attacks, a vaporized combination of THC and CBD worked better than THC alone, CBD alone, or a placebo. THC alone helped with pain, but not other...
info_outline
Tried Multiple Migraine Treatments Without Relief? Atogepant May Help
Migraine Minute News Update
A new real-world study shows atogepant (sold under brand name Qulipta) may quickly reduce migraine days—even for those who haven’t responded to other treatments. Molly O’Brien has more in this Migraine Minute News Update! Read more: CC License: Script: The GIANT study, published inThe Journal of Headache and Pain, offers real-world evidence that atogepant is a safe, well-tolerated, and effective for migraine prevention—among those whose prior treatments didn’t work. Researchers looked at the impact of 60 mg of atogepant, taken once daily in people with either high-frequency...
info_outline
Diabetes Drug May Cut Migraine Days in Half
Migraine Minute News Update
Can diabetes and weight loss drugs help with migraine relief? A new study suggests GLP-1 medications may significantly reduce migraine days. @ Molly O’Brien has more in this Migraine Minute News Update. Read More: Image and license to use: Headache. 2025; 00: 1-8. Script: GLP-1s….a drug class widely used for diabetes and weight loss treatment, may also help migraine. A small study published in Headache looked at liraglutide as an add-on treatment for unresponsive migraine in people with obesity who have tried at least two preventive migraine treatments. The study tracked 31...
info_outline
Major Study Shows Triptans Top Other Oral Acute Meds
Migraine Minute News Update
A major study found that oral triptans work better for the acute treatment of migraine, than newer drugs. Molly O’Brien breaks it all down in this Migraine Minute News Update. Read more: Images and License to use: BMJ 2024;386:e080107 Script: A major international study published in the British Medical Journal found triptans to be the most effective acute treatment for migraine. Researchers analyzed 137 clinical trials involving nearly 90,000 adults… comparing 17 oral treatments. They looked at how many people were pain-free two hours post-dose and how many were still pain-free at 24...
info_outline
Psychedelic Use Linked to Fewer Frequent Headaches
Migraine Minute News Update
A study in the Journal of Psychopharmacology found a surprising connection between psychedelic use and frequent bad headaches. Could psilocybin play a role in headache treatment? Molly O’Brien explains in this Migraine Minute News Update. Read more: Script: A new study in the Journal of Psychopharmacology shows that people who’ve used psychedelics like LSD or psilocybin may be less likely to experience frequent bad headaches. Researchers analyzed data from a large group of people in the UK and found that those who reported a lifetime use of classic psychedelics were 25% less likely...
info_outline
How Might Stress Trigger Migraine Pain?
Migraine Minute News Update
Scientists are learning how stress may trigger a series of brain responses that could be linked to migraine, at least in mice. Molly O’Brien has more in this Migraine Minute News Update. Source: Script: A study published in the Journal of Headache and Pain explains how stress can lead to migraine pain. Research in mice found that stress increases a brain chemical called PACAP-38. This chemical activates specific cells that release inflammatory substances. This series of events can affect the trigeminovascular system, which may trigger migraine pain. The study’s author notes that...
info_outline
FDA Approves Two New DHE Migraine Treatments for Fast Relief
Migraine Minute News Update
Two innovative DHE-based migraine treatments just earned FDA approval—offering some Americans new options for managing attacks. Molly O’Brien has details in this #MigraineMinute News Update. Read More: and *DHE is not safe for the management of hemiplegic migraine, migraine with brainstem aura, in people with certain comorbidities, or in those who take certain medications. Script: Many Americans with migraine now have two new treatment options, thanks to recent FDA approvals of Brekiya and Atzumi. Both drugs utilize Dihydroergotamine or DHE. While DHE for migraine has been around for...
info_outline
Navigating the 4th of July with Migraine: Triggers & Tips
Migraine Minute News Update
Celebrating the Fourth of July with migraine is not easy. The holiday can be packed with sensory overload and migraine triggers. In this Migraine Minute, Molly O’Brien shares tips to help you enjoy the celebration while protecting your health. Check out our updated triggers webpage: Reference: Script: While the Fourth of July can be a fun holiday to celebrate in the States, it can be tough for folks with migraine. Why? Well, there are so many factors that can be stacked against you. Think about it, heat, big crowds, staying up late, BBQ foods and drinks that might have triggering...
info_outline
Does PACAP 38 Work Differently Than CGRP?
Migraine Minute News Update
New research shows CGRP monoclonal antibody treatment may not prevent migraine attacks triggered by the neuropeptide PACAP-38. This study suggests PACAP-38 may act through a different pathway and could become a future preventive option for people who don’t respond to CGRP-based treatments. Molly O’Brien explains in this Migraine Minute News Update. Read More: Images courtesy: Springer Nature. The Journal of Headache and Pain. doi: 10.1186/s10194-025-02022-2 Creative Commons license: Script: Does PACAP 38 Work Differently Than CGRP? A new study published in the Journal of Headache...
info_outline
Can Erenumab Treat Medication Overuse Headache?
Migraine Minute News Update
A study published in JAMA Neurology shows that monthly erenumab injections may help treat medication overuse headache (MOH) in people with chronic migraine. While the 140 mg dose was effective for treating MOH, the 70 mg dose did not show a meaningful difference compared to placebo. Molly O’Brien explains in this Migraine Minute News Update. Read More: Image Courtesy: JAMA Neurology doi:10.1001/jamaneurol.2024.3043 Transcript: A study published in JAMA Neurology looked at the safety and efficacy of a CGRP monoclonal antibody for treating Medication Overuse Headache in people with...
info_outlineA new real-world study shows atogepant (sold under brand name Qulipta) may quickly reduce migraine days—even for those who haven’t responded to other treatments. Molly O’Brien has more in this Migraine Minute News Update!
Read more: http://bit.ly/3UcEuJN
CC License: https://creativecommons.org/licenses/by-nc-nd/4.0/
Script:
The GIANT study, published inThe Journal of Headache and Pain, offers real-world evidence that atogepant is a safe, well-tolerated, and effective for migraine prevention—among those whose prior treatments didn’t work.
Researchers looked at the impact of 60 mg of atogepant, taken once daily in people with either high-frequency episodic or chronic migraine. Many of the participants had already tried at least three other preventive treatments… including CGRP monoclonal antibodies.
Results? At 12 weeks, on average, participants saw a decrease of 6 migraine days and 11 headache days per month. In fact, nearly 60% of experienced at least a 50 percent drop in migraine days. Pain intensity, disability, and use of acute drugs also dropped.
Some saw improvement in migraine frequency within the first week.